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Tryptophan (W) is an essential amino acid which is primarily required for protein synthesis. It also acts as 5 
a precursor of key biomolecules for human health (serotonin, melatonin, tryptamine, niacin, nicotinamide 
adenine dinucleotide (NAD), phosphorylated NAD (NADP), quinolinic acid, kynureric acid, etc.). 
Among dietary proteins, milk proteins are particularly rich in W. W residues within milk proteins may be 
released by proteolytic/peptidolytic enzymes either as a free amino acid or as part of peptide sequences. 
Different W-containing peptides originating from milk proteins have been shown in vitro to display a 10 
wide range of bioactivities such as angiotensin converting enzyme (ACE) inhibition along with 
antioxidant, antidiabetic and satiating related properties. Free W has been shown in certain instances to 
have an effect on cognition and the aforementioned bioactive properties. However, a higher bioactive 
potency has generally been observed with specific W-containing peptides compared to free W. Since W is 
thermolabile, the impact of processing on the stability of W-containing peptides needs to be considered. 15 
Milk protein-derived W-containing peptides may have significant potential as natural health promoting 
agents in humans. 
1. Introduction 
The name “tryptophan” (W, molecular formula: C11H12N2O2, 
molecular mass: 204.23 Da) originates from the time when this 20 
amino acid was first isolated from a casein (CN) tryptic digest by 
Hopkins and Cole 1. Of the twenty conventional amino acids, W 
is the only one which possesses an indole structure. W is 
classified within the category of hydrophobic amino acids. It is 
formed through the condensation of serine (S) with an indole 25 
group. This reaction is catalysed by W synthase in lower 
organisms, including microorganisms. As an essential amino 
acid, it cannot be synthesised by humans and animals because 
they are lacking in W synthase. Therefore, W has to be supplied 
to the body by exogenous sources, notably through the diet 2,3. A 30 
requirement of 4 mg kg-1 day-1 for adults has been set by the 
WHO for healthy metabolism 4. W has been reported to be the 
amino acid with the lowest concentration within the human body 
5,6. W deficiencies can have several consequences for human 
health including the onset of diseases such as pellagra (caused by 35 
niacin deficiency), as well as psychological, cognitive and 
behavioral disorders such as dementia and depression 5,6. 
 In the human body, the primary function of W is protein 
synthesis, with the L isomer being the only one which can be 
incorporated in proteins 5,6. W is also a precursor for the synthesis 40 
of serotonin, melatonin, tryptamine, niacin, nicotinamide adenine 
dinucleotide (NAD), NAD phosphorylated (NADP), quinolinic 
acid and kynureric acid (Fig. 1) 2,5,6. Kynurenine acts as a 
precursor of kynurenic and quinolinic acid which are antagonists 
and agonists of the glutamate receptor, respectively. Kynurenine 45 
has also been shown to retard cataract formation due to its role as 
a UV filter in the retina 5. W is the sole precursor of serotonin, 
which has been reported to have an effect on psychological status 
and satiety in humans. This effect may be modulated by 
tryptamine, which results from the decarboxylation of W 5. A link 50 
between W and the immune response has also been suggested. It 
is thought that W breakdown can reduce T cell proliferation on 
the one hand. On the other hand, the metabolites generated within 
the kynurenine pathway (taking place in the immune system) can 
modulate various inflammatory responses 2.  55 
 W is found within a wide range of dietary proteins (See USDA 
National Nutrient Database for W 7). However, certain protein 
sources are richer in W than others. Several dietary proteins have 
been described as good sources of W (> 0.3% (w/w)), these 
include egg, soy, bean, seafood, poultry and milk proteins 7. The 60 
major milk proteins contain between 1 (- and -CN) and 13 
(lactoferrin – LF, Table 1) W residues per molecule. In general, 
whey proteins possess more W residues than CNs. In particular, 
-lactalbumin (-La), which possesses 4 W residues per 
molecule, shows the highest W content (5.3% (w/w); Table 1) of 65 
milk proteins. 
 Following milk protein digestion, free amino acids and 
peptides are released in the gastrointestinal tract (GIT). These 
free amino acids and peptides may have different beneficial 
effects as health promoting agents 8. Numerous studies have 70 
shown that milk proteins comprise specific peptide sequences, 
known as bioactive peptides (BAPs), which are able to modulate 
different key health biomarkers 9,10. Various antihypertensive, 
antioxidant, mineral binding, antimicrobial and anticancer 
activities have been demonstrated in vitro 11-15. A number of 75 
human intervention studies have concluded in positive health 
outcomes following the consumption of dairy products and milk 
protein-derived BAPs 16-24. 
 The detection of peptides within complex food protein 
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hydrolysates and biological fluids has been made easier with the 
enhanced precision of liquid chromatography mass-spectrometry 
(LC-MS) analysers 25. Furthermore, bioinformatic tools have 
allowed the establishment of structure-function relationships 
between BAPs and their in vitro bioactivity 26,27. In addition, 5 
peptide alignment strategies have made it possible to discriminate 
peptide motifs which correlate with specific bioactive properties 
28,29. Establishment of structure-function relationships has 
highlighted the importance of specific amino acid residues within 
BAPs. For example, Y, L, P and W residues appear to play a 10 
specific role in opioid, antioxidant, insulinotropic, along with 
angiotensin converting enzyme (ACE) and dipeptidyl peptidase 
IV (DPP-IV) inhibitory peptides 8,28,30,31. This review assesses the 
contribution of W and W-containing peptides to the bioactive 
properties of milk protein hydrolysates. The targeted release of 15 
free W and W-containing peptides during the digestion of milk 
proteins will be outlined. Furthermore, the literature on the 
stability of W and W-containing peptides following different 
processing conditions, which are relevant to food manufacture, 
will be assessed. 20 
 
Table 1: Percentage (% (w/w)) of tryptophan (W) residues found within the major milk proteins. 
Protein* Molecular mass (Da) 
Number of W 
residues per molecule 
Percentage of W in the 
protein (% w/w) 
-lactalbumin (P00711) 14186 4 5.3 
-lactoglobulin (P02754) 18281 2 2.0 
bovine serum albumin (P02769) 67206 2 0.6 
lactoferrin (P24627) 76145 13 3.2 
s1-casein (P02662) 20374 2 1.8 
s2-casein (P02663) 24349 2 1.5 
-casein (P02666) 23584 1 0.8 
-casein (P02668) 18975 1 1.0 
*The accession number for the protein is given in brackets 
 
 25 
2. Release of free W and W-containing peptides 
during the digestion of milk proteins 
A limited number of studies have investigated the release of 
peptides from milk proteins during gastrointestinal (GI) digestion 
in humans 32-36. Free W and/or W-containing peptides originating 30 
from milk proteins may be released in the GIT following the 
digestion of milk proteins 32,36,37. Furthermore, using in silico 
approaches, the release of free W and W-containing peptides by 
GI enzymes can be predicted (Table 2). Chymotrypsin, in 
particular, is able to cleave milk proteins at the C-terminus of W 35 
residues 38. In silico digestion of the major milk proteins with GI 
enzymes has shown that free W may be released by chymotrypsin 
from αs1-CN, α-La and bovine serum albumin (BSA). In addition, 
W-containing peptides with 2-71 amino acid residues may also be 
released from all major milk proteins (αs1-, αs2-, - and -CN, α-40 
La, -Lg, LF and BSA, Table 2). 
 However, to date, only a limited number of W-containing 
peptides have been identified in biological samples obtained from 
humans (Table 3), including the jejunal contents 32 and the sera 
24. Peptide cutter programs generally only allow prediction of 45 
peptides which may be released by one enzyme activity, while 
digestion in humans involves the hydrolytic activity of several 
enzymes (proteinases and peptidases). In general, the peptides 
which were predicted in silico to be released by GI enzymes 
(Table 2) have not been identified in the GIT (Table 3). However, 50 
larger β-CN peptides predicted to be released in silico (Table 2) 
may act as precursors of the five β-CN derived W-containing 
peptides which has been identified in the jejunal contents of 
humans 32. These peptide precursors may be further cleaved by 
carboxy- and aminopeptidases present in the GIT of humans 39,40. 55 
 In the late 1980’s, contaminated batches of W supplements 
caused several cases of eosinophilia myalgia syndrome, which 
was fatal in certain instances. However, it has been demonstrated 
that W is a non-toxic amino acid 41. Its median lethal dose (LD50) 
was determined as being as high as 1.6 g kg -1 in rats 42, 60 
corresponding to ~ 1.4 g kg -1 in humans 6. It is well accepted that 
free amino acids and peptides are more easily absorbed than 
unhydrolysed proteins 40,43,44. W is found in the circulation 
mainly in a bound form with BSA 6. However, W is thought to be 
able to cross the blood brain barrier (BBB) in a free form as it has 65 
a higher affinity for BBB transporters than for BSA 5. The 
transfer of W to the brain is thought to be reduced by the 
presence of large neutral amino acids (LNAA) which compete for 
the same transporter 6. In this context, W supplements, which are 
more concentrated than dietary sources, allow for its increased 70 
bioavailability in the brain 41. However, because the incorporation 
of W into proteins depends on the presence of other amino acids, 
it has been suggested that intake of W from supplements causes 
an imbalance which may not be consistent with efficient protein 
synthesis. Therefore, intake of dietary W appears more efficient 75 
for protein synthesis than W supplements 6. 
 Foltz, et al. 26 studied the intestinal stability of dipeptides in 
silico and in vitro. Most W-containing dipeptides found within 
the milk proteins which were evaluated, were not stable to in 
vitro intestinal digestion, with the exception of GW (LF (f124-80 
125) and LF (f466-467)). There are a limited number of reports of 
W-containing peptides being identified in the circulation of 
humans. LW, an ACE inhibitory peptide which is predicted to be 
released from s1-CN by pepsin (Table 3), was identified in the 
serum of human subjects who consumed a yoghurt beverage 85 
enriched with the lactotripeptides IPP and VPP 24. 
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Table 2: Free tryptophan (W) and W-containing peptides released by gastrointestinal enzymes following the in silico digestion of major milk proteins. In 
silico digestion was carried out with an in-house algorithm using the peptide cutter from Matlab (version 2014b, The MathWorks Inc., Natick, MA, USA). 
Protein* Enzyme Free W and W-containing peptides 
αs1-CN (P02662) CH-LO W 
 PEPS LW 
 PEPS2 DAYPSGAWYYVP 
 PEPS2 LW 
 TRYPS QFYQLDAYPSGAWYYVPLGTQYTDAPSFSDIPNPIGSENSEK 
 TRYPS TTMPLW 
 ELAS WY 
 CH-HI QLDAYPSGAW 
 CH-HI SDIPNPIGSENSEKTTMPLW 
 CH-LO DAYPSGAW 
αs2-CN (P02663) PEPS WDQVKRNAVPITPTL 
 PEPS WIQPKTKVIP 
 PEPS2 LNPWDQVKRNAVPITPTL 
 PEPS2 KTVYQHQKAMKPWIQPKTKVIPYVRYL 
 TRYPS FPQYLQYLYQGPIVLNPWDQVK 
 TRYPS AMKPWIQPK 
 ELAS NPWDQV 
 ELAS MKPWIQPKTKV 
 CH-HI QGPIVLNPW 
 CH-HI QHQKAMKPW 
 CH-LO NPW 
 CH-LO KPW 
β-CN (P02666) PEPS2 QSWMHQPHQPLPPTVMFPPQSV 
 TRYPS YPVEPFTESQSLTLTDVENLHLPLPLLQSWMHQPHQPLPPTVMFPPQSVLSLSQSK 
 ELAS WMHQPHQPL 
 CH-HI TESQSLTLTDVENLHLPLPLLQSWMHQPHQPLPPTVMFPPQSVLSLSQSKVLPVPQKAVPYPQRDMPIQAF 
 CH-LO QSWM 
κ-CN (P02668) PEPS2 QWQV 
 TRYPS SPAQILQWQVLSNTVPAK 
 ELAS QWQV 
 CH-HI AKPAAVRSPAQILQW 
 CH-LO QW 
α-La (P00711) CH-LO W 
 PEPS PEW 
 PEPS WCKDDQNPHSSNICNISCDK 
 PEPS2 PEWVCTT 
 PEPS2 QINNKIWCKDDQNPHSSNICNISCDK 
 PEPS2 TDDIMCVKKILDKVGINYW 
 PEPS2 DQW 
 TRYPS GYGGVSLPEWVCTTFHTSGYDTQAIVQNNDSTEYGLFQINNK 
 TRYPS IWCK 
 TRYPS VGINYWLAHK 
 TRYPS LDQWLCEK 
 ELAS PEWV 
 ELAS WCKDDQNPHSS 
 ELAS WL 
 ELAS DQWL 
 CH-HI GGVSLPEW 
 CH-HI QINNKIW 
 CH-HI LAHKALCSEKLDQW 
 CH-LO GGVSLPEW 
 CH-LO QINNKIW 
 CH-LO DQW 
β-Lg (P02754) PEPS2 LDIQKVAGTWYS 
 PEPS2 QKWENGECAQKKIIAEKTKIPAV 
 TRYPS VAGTWYSLAMAASDISLLDAQSAPLR 
 TRYPS WENGECAQK 
 ELAS GTWY 
 ELAS QKWENGECA 
 CH-HI LIVTQTMKGLDIQKVAGTW 
 CH-HI VEELKPTPEGDLEILLQKW 
 CH-LO DIQKVAGTW 
 CH-LO QKW 
BSA (P02769) CH-LO W 
 PEPS FWGK 
 PEPS WSVARL 
 PEPS2 FWGKY 
 PEPS2 LKAWSVARL 
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 TRYPS FWGK 
 TRYPS AWSVAR 
 ELAS DEKKFWGKY 
 ELAS WS 
 CH-HI GERALKAW 
 CH-LO KAW 
LF (P24627) PEPS APRKNVRW 
 PEPS CTISQPEW 
 PEPS KCRRWQW 
 PEPS TRVVW 
 PEPS2 APRKNVRWCTISQPEW 
 PEPS2 KCRRWQWRMKK 
 PEPS2 GRSAGWIIPMGI 
 PEPS2 SWTES 
 PEPS2 IWK 
 PEPS2 LRETAEEVKARYTRVVWCAVGPEEQKKCQQWSQQSGQNVTCATASTTDDCIV 
 PEPS2 TWNS 
 PEPS2 KDKKSCHTAVDRTAGWNIPMG 
 PEPS2 VKNDTVWENTNGESTADWAKN 
 TRYPS WCTISQPEWFK 
 TRYPS WQWR 
 TRYPS SAGWIIPMGILRPYLSWTESLEPLQGAVAK 
 TRYPS EDLIWK 
 TRYPS VVWCAVGPEEQK 
 TRYPS CQQWSQQSGQNVTCATASTTDDCIVLVLK 
 TRYPS ANEGLTWNSLK 
 TRYPS TAGWNIPMGLIVNQTGSCAFDEFFSQSCAPGADPK 
 TRYPS NDTVWENTNGESTADWAK 
 ELAS RWCTI 
 ELAS QPEWFKCRRWQWRMKKL 
 ELAS GWI 
 ELAS WTES 
 ELAS WKL 
 ELAS WCA 
 ELAS GPEEQKKCQQWS 
 ELAS TWNS 
 ELAS GWNI 
 ELAS WENTNGES 
 ELAS DWA 
 CH-HI APRKNVRW 
 CH-HI CTISQPEW 
 CH-HI KCRRW 
 CH-HI QW 
 CH-HI QLDQLQGRKSCHTGLGRSAGW 
 CH-HI LSW 
 CH-HI KECHLAQVPSHAVVARSVDGKEDLIW 
 CH-HI TRVVW 
 CH-HI CAVGPEEQKKCQQW 
 CH-HI LAVAVVKKANEGLTW 
 CH-HI NSLKDKKSCHTAVDRTAGW 
 CH-HI VKNDTVW 
 CH-HI ENTNGESTADW 
 CH-LO APRKNVRW 
 CH-LO CTISQPEW 
 CH-LO KCRRW 
 CH-LO QW 
 CH-LO GRSAGW 
 CH-LO SW 
 CH-LO IW 
 CH-LO TRVVW 
 CH-LO CAVGPEEQKKCQQW 
 CH-LO TW 
 CH-LO TAVDRTAGW 
 CH-LO VKNDTVW 
 CH-LO ENTNGESTADW 
*The accession number for the protein is given in brackets 
CN: casein; -La: -lactalbumin; -Lg: -Lactoglobulin; BSA: bovine serum albumin; LF: lactoferrin 
Enzymes used in the peptide cutter were: pepsin pH 1.3 (PEPS) andpH  > 2 (PEPS2), pancreatic elastase (ELAS), trypsin (TRYPS), chymotrypsin high 
(CH-HI) and low (CH-LO) specificity 
 5 
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Table 3: Milk protein-derived tryptophan (W)-containing peptides identified in human biological samples. 
Parent protein Fragment Peptide sequence Location Reference 
β-CN (P02666) 140-148 LQSWMHQPH Intestine 32 
 142-148 SWMHQPH  32 
 143-148 WMHQPH  32 
 143-154 WMHQPHQPLPPT  32 
 143-155 WMHQPHQPLPPTV  32 
CNs/whey diverse LW Serum 24 
The accession number of β-CN is given in brackets 
CN: casein 
 
3. Effect of W and W-containing peptides on 5 
psychological and cognitive function 
W and W-containing peptides have been shown to play a key role 
in various bioactive properties which may be relevant to the 
management of diseases in humans. Their role in 
psychological/cognitive function and as antihypertensive, 10 
antioxidant, antidiabetic and satiating agents will be outlined in 
the following sections.  
 Intake of W has been linked with an increase in serotonin level 
in the brain of animal 45 and human subjects 41. Increased 
serotonin levels in the central nervous system may beneficially 15 
modulate stress-related and cognitive function 41,46-49. A 
significant increase in plasma W:LNAA ratio was seen, which 
induced anxiolytic-like effects in rats fed with -La enriched 
whey proteins (190 g kg-1). The anxiolytic effects may be related 
to an increase in serotonin synthesis and release 45. Consumption 20 
of -La, a W rich protein, induced a 48% increase in plasma 
W:LNAA ratio compared to a CN diet 50. This increase was 
thought to be followed by a higher serotonin concentration in the 
hypothalamus of human subjects 50,51. A positive effect on 
depressive mood and a better ability to cope with stress 25 
(reduction of cortisol-related stress) was seen in stress-vulnerable 
human subjects 50. Evening intake of α-La induced a relatively 
high increase in plasma W:LNAA ratio (+ 130%, 2 h after intake) 
followed by improved morning alertness (reduced sleepiness) and 
vigilance performance which were explained by a better sleep 30 
quality 52. Similarly in another study, free W intake was shown to 
improve cognitive function (significantly shorter reaction time in 
a memory scanning test) in highly stressed human subjects 51. 
However, this positive effect was not seen in low stress 
vulnerable subjects. Increased serotonin level in highly stressed 35 
subjects may have caused a reduction of stress levels which was 
followed by better cognitive performances 51. Other studies have 
also reported an increase in the plasma W:LNAA ratio in healthy 
females following -La intake (40 g). However, this was not 
followed by beneficial modifications in subjective ratings of 40 
mood or anxiety 53. 
 It has been proposed that the plasma W:LNAA ratio may be 
further increased by the intake of hydrolysed vs. intact -La 46. 
To date, it appears that most studies involving dietary protein 
hydrolysate effects on plasma W and psychological outcomes 45 
have been conducted with the proprietary egg protein 
hydrolysate, LumiVida™ (DSM, Delft, The Netherlands) 54-56.
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Fig. 1: Structure of tryptophan (W) and biomolecules with W-like structures. The structures were taken from www.chemspider.com. 
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4. ACE inhibitory properties of W and W-
containing peptides 
ACE is a metabolic enzyme which is involved in the cleavage of 
the potent vasodilator bradykinin, resulting in a loss in its activity 
30. ACE inhibition has therefore been suggested as a means to 5 
reduce blood pressure. Numerous studies have focused on food 
protein-derived peptides with ACE inhibitory properties. A large 
number of human intervention studies have been conducted with 
milk protein-derived ACE inhibitory peptides and more 
particularly with the CN-derived lactotripeptides IPP and VPP 10 
57,58. 
 Several in silico approaches including quantitative structure 
activity relationship (QSAR) and molecular docking have been 
utilised in an attempt to predict the ACE inhibitory activity of 
peptides. These studies have allowed a better understanding of 15 
the structural features of peptides displaying ACE inhibitory 
activity (Fig. 2). These analyses indicated that the presence of 
branched chain amino acids (L and I) or C and G at the N-
terminus and R, W, P, K, F or Y at the C terminus are associated 
with potent ACE inhibitory activity 24,27,30,59. 20 
 
 
 
 
 25 
 
 
 
 
 30 
 
 
 
 
 35 
Fig. 2: Structural characteristics of potent angiotensin converting enzyme 
(ACE) inhibitory peptides 24,27,30 
 
 
 Several W-containing peptides displaying low ACE half 40 
maximal inhibitory concentration (IC50) values have been 
reported in the literature, some of which are listed in Table 4. 
These peptides have been identified within all the major milk 
proteins with the exception of -CN. Their IC50 values vary 
between 0.7 (KGYGGVSLPEW, α-La (f16–26)) to 372 µM 45 
(VGINYWLAHK, -La (f99-108)). Virtual screening approaches 
such as molecular docking have been used to predict the 
sequences of peptides with potent ACE inhibitory properties 60,61. 
Selected W-containing dipeptides (AW (s1-CN (f163-164)), IW 
(α-La (f 59-60) and LF (f 267-268)) and VW (LF (f 346-347) and 50 
LF (f 548-549)) were shown to be competitive inhibitors of 
human ACE 62,63. The -La-derived peptides, IW and WL (α-La 
(f 104-105) and α-La (f 118-119)) were identified in milk protein-
based infant formulae 64 and in a whey protein hydrolysate 
generated with a combination of chymotrypsin and thermolysin 55 
62. The yield for the release of IW was estimated between 4-19% 
in the infant formulae 64 and at 50% (w/w) in a whey protein 
hydrolysate 62. While that of WL was 4% (w/w) in a whey protein 
hydrolysate 62. Simulated gastrointestinal digestion (SGID) 
revealed that AW and IW, when present in an hydrolysate, were 60 
stable to the hydrolytic action of pepsin but were significantly 
degraded (59 and 40% (w/w), respectively) on incubation with 
pancreatic enzyme activities 62. 
 Localisation of the W residue at the C-terminal position of 
dipeptides (RW and VW) has been correlated with higher ACE 65 
inhibitory properties as compared to the reverse peptides (WR 
and WV). These differences were explained by the fact that 
higher hydrophobic interactions at the S2’ hydrophobic sub-site 
of the C-domain of the ACE active site could take place when W 
was located at the C-terminal side of dipeptides 63. 70 
 LW (s1-CN (f198-199)) and IW were administered to 
spontaneous hypertensive rats (SHR) at 10 and 60 mg kg-1, by 
intravenous injection and oral administration, respectively 65. LW 
caused a decrease in systolic blood pressure (SBP) of -45 and -22 
mmHg after intravenous injection and oral administration, 75 
respectively. While IW reduced SBP by -55 and -22 mmHg after 
intravenous injection and oral administration, respectively 65. 
5. Antioxidant activity of W and W-containing 
peptides 
Free amino acids and milk protein-derived peptides may act as 80 
antioxidant compounds. The mechanisms involved in the 
antioxidant activity comprise radical scavenging of oxidative 
species and the modulation of enzymes involved in the in vivo 
oxidative system 12. Milk protein-derived peptides which are able 
to scavenge antioxidant species are generally short (< 11 amino 85 
acid residues) peptides containing hydrophobic (P, H, Y and W) 
and/or sulphur (C and M) residues 9,11,66-71. A study on the 
antioxidant activity of 18 free amino acids (V, I, D, T, L, E, A, 
M, Y, H, F, W, C, N, K, G, Q and P) using the ORAC assay has 
shown that W displayed the highest activity 72. Another study has 90 
assessed the antioxidant activity of free amino acids using the 
2,2’-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) ABTS 
assay. Four amino acids displayed a scavenging activity of the 
ABTS radical in the following order C > W > Y > H 73. Similarly, 
the importance of W has been demonstrated in the scavenging of 95 
reactive oxygen and nitrogen species 3 as well as in the 
scavenging of peroxyl radical and the inhibition of linoleic acid 
autoxidation 74. It has been suggested that phenol and indole 
amino acids within peptides may act as hydrogen donors, 
resulting in the formation of stable radicals and a reduction in the 100 
rate of oxidation propagation 11,69,72. 
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Table 4: Half maximal inhibitory concentration (IC50) of tryptophan (W)-containing peptides from milk proteins with angiotensin converting enzyme 
(ACE) inhibitory properties. 
Peptide sequence * Protein fragment ACE IC50 (µM) Reference 
KGYGGVSLPEW α-La (f16–26) 0.7 
75 
VW LF (f346-347), LF (f548-549) 1.6 
59 
IW α-La (f59-60), LF (f267-268) 2 
59 
FW BSA (f133-134) 5.9 
27 
AW s-C f 10 
59 
RW LF (f7-8), LF (f21-22) 16 
59 
DKVGINYW α-La (f97–104) 25.4 
75 
GW LF (f124-125), LF (f466-467) 30 
59 
LQKW β-Lg (f58–61) 34.7 
76 
YW -Laf 43.7 
27 
TTMPLW s-C f 51 
77 
WLAHK α-La f 77 
78 
DAYPSGAW s-C f 98 
77 
WI αs2-CN (f193-194), LF (f125-126) 100 
24 
WL α-La (f104-105), α-La (f118-119) 105 
24 
WY αs1-CN (f164-165), α-La (f19-20) 113 
24 
LW s-C f 144 
24 
VGINYWLAHK α-La f 372 
78 
* Peptide sequences are ordered by increasing ACE inhibitory IC50 value 
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 The inhibition and activation of metabolic enzymes involved 
in the oxidative system have also been demonstrated in a few 
studies with W-containing peptides. The role of W in xanthine 
oxidase (XO) inhibition was hypothesised based on its structural 
similarities with its natural substrate, xanthine (Fig. 1), and a drug 10 
inhibitor of XO, Allopurinol 79. This was confirmed by the fact 
that out of the 20 amino acids tested, W was the only one to 
display inhibitory properties against XO 80. The inhibition of 
xanthine oxidase (XO) in vitro by free W, RW, IW, KW, WV and 
VW has been reported 79,80. Similarly, LF hydrolysates were also 15 
able to inhibit XO. This was attributed to the W-containing 
peptides within the hydrolysates as shown following further 
enrichment of the hydrolysates using activated carbon 79. Pro-
oxidant activity of free W has been reported in Caco-2 cells 81. 
Interestingly, an adaptive response through the nuclear factor 20 
(erythroid-derived 2)-like 2 (Nrf-2) pathway was demonstrated, 
which resulted in an increase in glutathione peroxidase 
transcription level. 
 A compendium of antioxidant activity of W and W-containing 
peptides, as determined by different assays, is presented in Table 25 
5. Free W displays a lower anti-oxidant capacity than peptides, 
e.g., with 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging. 
However, in other instances, free W antioxidant activity was as 
high as that of W-containing peptides such as with the oxygen 
radical absorbance capacity (ORAC) assay and with XO 30 
inhibition (Table 5). In addition, the peptide sequence also 
affected the antioxidant activity as demonstrated in studies 
conducted with reverse peptides 79,82,83 or when substituting 
amino acids in peptides 74. It is interesting to note that certain 
peptides yielded good antioxidant properties across different 35 
assays (Table 5). This was the case for WV and VW which were 
able to scavenge DPPH and superoxide (SO) radicals and inhibit 
XO; for WY which displayed ORAC activity and scavenged 
DPPH and for KW which scavenged DPPH and inhibited XO. 
6. Antidiabetic potential of W and W-containing 40 
peptides 
The consumption of intact and hydrolysed milk proteins has been 
linked, in certain instances, with an increase in insulin secretion 
in the post-prandial phase. This insulinotropic effect may be 
followed by a reduction in serum glucose both in animal models 45 
84-86 and in humans 16,18,87-90. The insulinotropic effect of milk 
proteins has been linked with an increase in plasma amino acid 
level, in particular branched chain amino acids (BCAA), 
following the consumption of milk proteins. A human study has 
reported on the insulinotropic and serum glucose lowering effect 50 
of free W. It was shown that intravenous infusion of W (amount 
infused: 2.5-22.5 g) increased plasma insulin, displaying a similar 
potency as L 91. However, the role of W in insulin secretion has 
not been extensively studied. This may arise from limitations in 
the analytical methodologies used to quantify free amino acids 55 
which often lead to a heat-induced destruction of W, thus making 
it challenging to quantify 92. However, different strategies for W 
residue protection during acid hydrolysis involving the utilisation 
of antioxidants (e.g. thioglycolic acid), reducing agents (e.g. 
pyridine borane) and organic acids (e.g. p-toluene sulfonic acid) 60 
have been suggested. A lower level of W degradation is generally 
observed during alkaline hydrolysis in the absence of oxygen 93. 
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Table 5: Tryptophan (W)-containing peptides from milk proteins with antioxidant activity. 
Peptide sequence Protein fragment 
SO EC50 
(mM) 
DPPH EC50 
(mM) 
ORAC activity 
(T.E./μmol) 
XO IC50 
(µM) 
W diverse na 358.5 
94
 4.65 
72
 1259.8 
79
 
WV α-La (f 26-27) 131.02 
94
 242.0 
94
 na 1195.7 
79
 
VW LF (f 346-347), LF (f 548-549) 114.52 
94
 654.2 
94
 na 1301.7 
79
 
RW LF (f 7-8), LF (f 21-22) na na na 1136.9 
80
 
KW -Lg (f 60–61) na 4.14 
83
 na 1450.9 
80
 
IW α-La (f 59-60), LF (f 267-268) na na na 1046.6 
80
 
WC α-La (f 60-61), LF (f 8-9), LF (f 348-348) na 0.26 
83 na na 
WY αs1-CN (f 164-165), α-La (f 19-20) na 1.28 
83 7.67 
95
 na 
WpY* αs1-CN (f 164-165), α-La (f 19-20) na 2.43 
83
 na na 
WL α-La (f 104-105), α-La (f 118-119) na 2.71 
83
 na na 
WQ -CN (f 76-77), LF (f 22-23) na 3.92 
83
 na na 
WF LF (f16-17) na 4.20 
83 na na 
WR LF (f24-25) na 4.43 
83 na na 
WT LF (f138-139) na 4.92 
83 na na 
WN LF (f448-449), LF (f467-468) na 4.92 
83 na na 
YW α-La (f 103-104) na 0.57 
83
 na na 
LW LF (f198-199) na 1.71 
83
 na na 
FW BSA (f133-134) na 3.04 
83
 na na 
GW LF (f124-125), LF (f466-467) na 3.68 
83
 na na 
SW -CN (f 157-158), LF (f137-138) na 3.97 
83
 na na 
EW α-La (f 25-26), LF (f15-16) na 3.07 
83
 na na 
WIQP αs2-CN (f 193-196) na 2.1 
96
 na na 
VAGTWY -Lg (f 15–20) na na 5.63 
97
 na 
WYS -Lg (f 19–21) na na 4.45 
95
 na 
WYSL -Lg (f 19–22) na na 4.51 
95
 na 
WYSLA -Lg (f 19–23) na na 4.59 
95
 na 
WYSLAMAASDI -Lg (f 19–29) na na 2.62 
72
 na 
*pY: phosphorylated tyrosine 
CN: casein; α-La: α-lactalbumin; β-Lg: β-lactoglobulin; LF: lactoferrin; BSA: bovine serum albumin. 
EC50: half maximal effective concentration; IC50: half maximal inhibitory concentration. 
DPPH: 2,2-diphenyl-1-picrylhydrazyl scavenging activity; na: not available; ORAC: Oxygen radical absorbance capacity; SO: superoxide scavenging 5 
activity; T.E.: Trolox equivalent; XO: xanthine oxidase. 
 
 DPP-IV is a metabolic enzyme which is responsible for the 
cleavage and subsequent inactivation of the incretin hormones 
glucagon like peptide 1 (GLP-1) and glucose inhibitory 10 
polypeptide (GIP) 98. These incretins, which have been shown to 
have an insulinotropic activity during the post-prandial phase, 
contribute to the regulation of serum glucose levels in humans. 
Therefore, inhibition of DPP-IV is a strategy which is being 
employed, notably with pharmaceutical drugs (gliptins) to help in 15 
the management of type 2 diabetes 99. Several food protein 
hydrolysates have been shown to display DPP-IV inhibitory 
properties in vitro 100. Out of the 20 conventional amino acids, it 
was shown that M, L and W were able to inhibit DPP-IV 80. 
However, their IC50’s were relatively high (> 2000 µM). In 20 
certain instances specific peptide sequences have been linked 
with DPP-IV inhibition 94,101-105. Milk protein-derived DPP-IV 
inhibitory peptides generally have an IC50 value in the µM range 
28, which is several orders of magnitude higher than that of 
gliptins (nM) 106. To date, four in vivo studies have demonstrated 25 
that food protein hydrolysates or peptides with in vitro DPP-IV 
inhibitory properties were able to induce an increased insulin 
secretion and a reduction in plasma glucose following an oral 
glucose tolerance test in rodents. This was the case with a tryptic 
digest of β-Lg administered (300 mg kg-1 body weight) to mice 30 
107, the peptide LPQNIPPL (β-CN (f70-77)) isolated from Gouda-
type cheese, administered (300 mg kg-1 body weight) to rats 108 
and porcine and Atlantic salmon skin gelatin hydrolysates 
administered (300 mg day-1 for 42 days) to streptozotocin-
induced diabetic rats 109,110. The insulinotropic effects observed 35 
were only directly linked with DPP-IV inhibition in vivo in two 
instances where plasma DPP-IV activity was shown to be 
reduced following the ingestion of a DPP-IV inhibitory porcine 
110 or Atlantic salmon skin gelatin hydrolysate 109. 
 A limited number of potent DPP-IV inhibitory peptide 40 
sequences have been identified to date. While several DPP-IV 
inhibitory peptides possess between 2-8 amino acids 111,112, 
longer peptide sequences with > 13 amino acid residues have also 
been identified 113. DPP-IV IC50 values of W and W-containing 
peptides inhibitors of DPP-IV are listed in Table 6. Their IC50 45 
values vary between 37.8 (WR) to 4280.4 µM (W). The peptides 
originate from all the major milk proteins with the exception of -
CN. 
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Table 6: Half maximal inhibitory concentration (IC50) of tryptophan (W)-containing peptides from milk proteins with dipeptidyl peptidase IV (DPP-IV) 
inhibitory properties. 
Peptide sequence * DPP-IV IC50 (µM) Protein fragment Reference 
WR 37.8 LF (f24-25) 83 
WK 40.6 LF (f268-269) 83 
WL 43.6 -La (f104-105), -La (f118-119) 83 
WV 65.7 -La (f26-27) 94 
TW 84 -Lg (f18-19), LF (f447-448) 114 
WA 92.6 LF (f560-561) 83 
WQ 120.3 -CN (f76-77), LF (f22-23) 83 
WI 138.7 s2-CN (f193-194), LF (f125-126) 
83 
WLAHKALCSEKLDQ 141 -La (f104-117) 102 
WN 148.5 LF (f448-449), LF (f467-468) 83 
VAGTWY 174 -Lg (f15-20) 115 
WIQP 237.3 s2-CN (f193-196) 
96 
WM 243.1 -CN(f158-159) 83 
WY 281 s1-CN (f164-165), -Lg (f19-20) 
83 
WLAHKAL 286 -La (f104-110) 102 
WC 420 -La (f60-6), LF (f8-9), LF (f347-348) 83 
WT 482.1 LF (f138-139) 83 
WS 643.5 LF (f361-362), BSA (f213-214) 83 
WRM 673 LF (f24-26) 116 
LW 993.4 s1-CN (f198-199) 
83 
W 4280.4 all 80 
*Peptide sequences are ordered by increasing DPP-IV inhibitory IC50 value 
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 An attempt to link in vitro DPP-IV inhibitory properties to the 
physicochemical characteristics (molecular mass, hydrophobicity 
hydrophobic moment (μH), isoelectric point (pI) and charge) of 
the peptides has been conducted 117. However, no obvious 10 
relationship between the physicochemical characteristics of the 
peptides and their bioactivity could be determined. In contrast, 
other specific features in DPP-IV inhibitory peptide sequences 
have been shown to correlate with their in vitro activity. It was 
reported that hydrophobic peptides with Xaa-Pro, Pro-Xaa or 15 
Xaa-Ala (with Xaa, an amino acid residue) sequences may be 
relatively potent DPP-IV inhibitors 118. Different structural 
features have been elucidated from relatively potent DPP-IV 
inhibitory peptides (with IC50 values < 200 µM) using a peptide 
alignment approach. This analysis revealed that these peptides 20 
generally contained a W at the N-terminus and/or a Pro at 
position 2 28. These characteristic features of DPP-IV inhibitory 
peptides were further confirmed in a more recent study where a 
similar approach was taken 29. Similarly, analysis of a dipeptide 
library revealed that the most potent DPP-IV inhibitory peptides 25 
generally contained a W residue at the N-terminal position 114. 
Interestingly, the specific location of W at the N-terminus of 
peptides is crucial for DPP-IV inhibitory activity. It was shown 
with dipeptide isomers that DPP-IV inhibitory activity was 
significantly reduced or lost when the W residue was located at 30 
the C-terminal position of the peptide 83. 
 Several W-containing peptides were shown to be non-
competitive, linear mixed- or parabolic mixed-type inhibitors of 
DPP-IV 83,94,116,119. This suggests that these peptides do not 
directly bind to the active site of DPP-IV 94,120. Taking in silico 35 
approaches, it was proposed that W-containing peptides were 
likely to bind to a secondary binding site located in the 
neighborhood of the active site of DPP-IV 80. Certain W-
containing peptides appear to act through different mechanisms 
which are still not fully understood and would merit more 40 
investigation since these peptides appear to be relatively potent 
DPP-IV inhibitors. 
7. Satiating properties of W and W-containing 
peptides 
Consumption of milk proteins has been proposed as a means to 45 
increase satiety in humans 87,121-123. The satiating effects of milk 
proteins are thought to involve the kinetics of amino acid 
appearance in the circulation and the rheological properties of the 
proteins in the GIT 124. Satiating effects have particularly been 
observed with whey proteins 125-127, which are digested faster than 50 
CNs 40,128. In particular, when -La was administered at breakfast 
to adults, a subsequent 25% reduction in energy intake in an ad 
libitum lunch was seen 129. No effect was seen with CN, whey, 
and whey with caseinomacropeptide (CMP) 129. 
 A link between serotonin activation and milk protein intake 55 
has been suggested. This has been explained by the fact that milk 
proteins are a source of W, the sole precursor of serotonin 130. 
Consumption of -La has been shown to increase plasma W in 
rats 45 and in humans 50,129, which may result in higher 
hypothalamic serotonin concentrations 50. Different milk protein 60 
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(whey and CN-derived) hydrolysates have been shown to act as 
serotonin 5-HT2C receptor agonist in embryonic kidney cell lines 
(HEK 293A) 131,132. While no effect was seen in vivo with the 1 
kDa permeate of a whey protein hydrolysate, the 1 kDa permeate 
of a CN hydrolysate was show to yield a significant reduction in 5 
cumulative food intake when administered intraperiteonally (500 
mg kg−1 body weight) to mice 131. 
8. Effect of processing conditions on W stability 
and bioactivity 
The stability of W and W-bound peptides/proteins to different 10 
processing conditions has been reviewed 92. W is relatively stable 
to processing conditions (steam sterilisation, industrial and home 
cooking) in comparison to other amino acids such as K, M and C 
92,133. However, the application of severe processing (heat in the 
presence of oxygen and sunlight exposure) applied to milk 15 
proteins can lead to the degradation of W and subsequently to 
reduced bioavailability or the formation of antinutritional and 
toxic/carcinogenic (carboline and Maillard) compounds 92. The 
reactivity (oxidation and substitution reactions) of W to different 
chemicals has been attributed to its indole structure. At 20 
temperatures > 100C, the degradation of W in acidic or basic 
conditions requires the presence of oxygen. It was estimated that 
in sterilising conditions (125C, 30 min), only 1% of W would be 
lost from CNs at pH 8.0 92. 
 The condensation of W with aldehydes leads to the generation 25 
of -carboline or Maillard like products 93. Maillard reactions 
occur between primary amino (ϵ- or -NH2) groups and reducing 
carbohydrates following heat treatment. The ϵ-NH2 group from 
W has been shown to be able to participate in Maillard reactions 
93. In addition, W may be further degraded by oxidative species 30 
which are generated during Maillard reactions 134. The oxidative 
degradation of W via Maillard reaction products is also termed 
glycoxidation (glycation and oxidation). W glycoxidation only 
appears to occur in native -La. This may arise from the fact that 
W residues within heat-denatured -La are not easily accessible 35 
to radicals due to the formation of -La aggregates 134. Similarly, 
the effect of lipid-derived oxidative products on the reduced 
bioavailability of W (-27.9%) from whey proteins following 
storage at 37C for 4 weeks has been reported 133. 
9. Conclusion 40 
W is a central amino acid residue for human nutrition as shown 
by its numerous physiological functions in the body. Dietary 
sources of W have been reported to be more efficient than W 
supplements in contributing to the primary role of W in the 
human body, i.e., protein synthesis. In this context, dietary 45 
sources of W such as milk proteins appear to be relevant for 
human nutrition. In addition, milk protein-derived W-containing 
peptides have been shown to display a wide range of bioactive 
properties. Several W-containing peptides have been identified in 
vitro for their potential antihypertensive, antioxidant and 50 
antidiabetic properties. In addition, W is generally considered to 
be stable to conventional processing as applied during food 
manufacture. The detection of W and W-containing peptides still 
appears to be challenging namely due to the oxidation of W 
which may be caused by the severe conditions applied during 55 
acid and alkaline hydrolysis of proteins. These analytical 
limitations may have hindered the discovery of novel W-
containing BAPs from milk. However, there is strong evidence in 
the scientific literature suggesting that W and W-containing 
BAPs originating from milk proteins may help to improve human 60 
health. 
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